SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

FDA Requires Inovio to Submit Draft Voceryq Study Protocol by End of 2026

The FDA requires Inovio Pharmaceuticals to submit a draft protocol for Voceryq’s confirmatory study by the end of 2026.

INO

Related stories